Wuxi Hailun Bio-Technology

Wuxi Hailun Bio-Technology is a clinical-stage biotechnology company based in Wuxi, China, specializing in the development of small molecule drugs for oncology and metabolic disorders. The company operates as a key research and development subsidiary of Simcere Pharmaceutical Group, focusing on precision medicine and targeted therapies. Its pipeline includes several innovative candidates such as Tuvonitinib (HL-085), a MEK1/2 inhibitor currently in clinical trials for melanoma and other solid tumors. Wuxi Hailun integrates advanced medicinal chemistry and biological evaluation to transition early-stage discoveries into clinical assets. The company's efforts are central to Simcere's broader strategy of expanding its portfolio in high-growth therapeutic areas.